Patients taking Plaquenil (hydroxychloroquine) require regular eye examinations because, although the medication is highly effective for treating conditions such as rheumatoid arthritis and lupus, it can rarely cause retinal toxicity. Hydroxychloroquine toxicity can affect the macula, the central part of the retina responsible for detailed vision. In its early stages, retinal damage may occur without noticeable symptoms, making routine screening essential for detecting changes before vision is permanently affected.

Two of the most important screening tests for patients taking Plaquenil are visual field testing and optical coherence tomography (OCT). Visual field testing evaluates how well a patient sees in different areas of their central vision and can detect subtle functional changes that may indicate early retinal toxicity. OCT provides detailed cross-sectional images of the retina, allowing eye care providers to identify microscopic structural changes in the retinal layers that may occur before significant vision loss develops. Together, these tests provide complementary information about both retinal function and anatomy.

Regular monitoring is critical because retinal damage from hydroxychloroquine is generally irreversible. However, when toxicity is detected early, discontinuing the medication in consultation with the patient's prescribing physician can help prevent further progression and preserve vision. Current screening guidelines recommend a baseline eye examination followed by periodic testing based on factors such as dosage, duration of use, kidney function, and other individual risk factors.

By combining visual field testing with OCT imaging, eye care providers can detect the earliest signs of hydroxychloroquine-related retinal toxicity and provide timely recommendations for patient care. This proactive approach helps balance the significant medical benefits of Plaquenil with the need to protect long-term visual health.